Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors–a systematic review and meta-analysis
S Hussaini, R Chehade, RG Boldt, J Raphael… - Cancer Treatment …, 2021 - Elsevier
Background The use of immune checkpoint inhibitors (ICIs) has become standard therapy in
many tumor sites. The aim of this study is to systematically review the literature to determine …
many tumor sites. The aim of this study is to systematically review the literature to determine …
[HTML][HTML] Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta …
X Zhou, Z Yao, H Yang, N Liang, X Zhang, F Zhang - BMC medicine, 2020 - Springer
Background A number of studies have reported an association between the occurrence of
immune-related adverse events (irAEs) and clinical efficacy in patients undergoing treatment …
immune-related adverse events (irAEs) and clinical efficacy in patients undergoing treatment …
Assessment of blood tumor mutational burden as a potential biomarker for immunotherapy in patients with non–small cell lung cancer with use of a next-generation …
Z Wang, J Duan, S Cai, M Han, H Dong, J Zhao… - JAMA …, 2019 - jamanetwork.com
Importance Tumor mutational burden (TMB), as measured by whole-exome sequencing
(WES) or a cancer gene panel (CGP), is associated with immunotherapy responses …
(WES) or a cancer gene panel (CGP), is associated with immunotherapy responses …
ECOG performance status≥ 2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors—a systematic …
FG Dall'Olio, I Maggio, M Massucci, V Mollica… - Lung Cancer, 2020 - Elsevier
Objectives ICIs have been approved and are routinely administered regardless of
performance status (PS), despite randomized clinical trials of ICIs alone or combined with …
performance status (PS), despite randomized clinical trials of ICIs alone or combined with …
Association of anti-TNF with decreased survival in steroid refractory ipilimumab and anti-PD1–treated patients in the Dutch Melanoma Treatment Registry
RJ Verheijden, AM May, CU Blank, MJB Aarts… - Clinical Cancer …, 2020 - AACR
Purpose: Unleashing the immune system by PD-1 and/or CTLA-4 blockade can cause
severe immune-related toxicity necessitating immunosuppressive treatment. Whether …
severe immune-related toxicity necessitating immunosuppressive treatment. Whether …
[HTML][HTML] Association of immune related adverse events with efficacy of immune checkpoint inhibitors and overall survival in cancers: a systemic review and meta …
Y Fan, W Xie, H Huang, Y Wang, G Li, Y Geng… - Frontiers in …, 2021 - frontiersin.org
Objectives Immune checkpoint inhibitors (ICIs) have brought impressive benefits to cancer
patients, however often accompanied with immune-related adverse events (irAEs). We …
patients, however often accompanied with immune-related adverse events (irAEs). We …
[HTML][HTML] Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab
I Yamauchi, A Yasoda, S Matsumoto, Y Sakamori… - PLoS …, 2019 - journals.plos.org
Background Blocking the PD-1 pathway induces immune-related adverse events (irAEs)
which often involve the thyroid gland (thyroid irAEs). Clinical features of a thyroid irAE …
which often involve the thyroid gland (thyroid irAEs). Clinical features of a thyroid irAE …
Immunotherapy-mediated thyroid dysfunction: genetic risk and impact on outcomes with PD-1 blockade in non–small cell lung cancer
Purpose: Genetic differences in immunity may contribute to toxicity and outcomes with
immune checkpoint inhibitor (CPI) therapy, but these relationships are poorly understood …
immune checkpoint inhibitor (CPI) therapy, but these relationships are poorly understood …
[HTML][HTML] Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study
Background Immune checkpoint inhibitors (ICIs) have improved survival and are
increasingly used for non-small cell lung cancer. However, use may be limited by immune …
increasingly used for non-small cell lung cancer. However, use may be limited by immune …
[HTML][HTML] Effectiveness and safety of immunotherapy in NSCLC patients with ECOG PS score≥ 2–systematic review and meta-analysis
Abstract Background Immune checkpoint inhibitors (ICIs) are standard of care in advanced
non-small cell lung cancer (NSCLC), however their status in patients with poor performance …
non-small cell lung cancer (NSCLC), however their status in patients with poor performance …